AEterna Zentaris Stock Price, News & Analysis (NASDAQ:AEZS)

$1.88 -0.01 (-0.53 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$1.88
Today's Range$1.85 - $1.94
52-Week Range$0.78 - $3.75
Volume49,908 shs
Average Volume786,764 shs
Market Capitalization$30.29 million
P/E Ratio-1.04
Dividend YieldN/A
Beta0.6

About AEterna Zentaris (NASDAQ:AEZS)

AEterna Zentaris logoAeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Receive AEZS News and Ratings via Email

Sign-up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:AEZS
CUSIPN/A
Phone+1-843-9003223

Debt

Debt-to-Equity RatioN/A
Current Ratio2.32%
Quick Ratio2.32%

Price-To-Earnings

Trailing P/E Ratio-1.03867403314917
Forward P/E Ratio-1.25
P/E GrowthN/A

Sales & Book Value

Annual Sales$910,000.00
Price / Sales33.96
Cash FlowN/A
Price / CashN/A
Book Value$0.48 per share
Price / Book3.92

Profitability

Trailing EPS($1.81)
Net Income$-24,950,000.00
Net Margins-2,338.61%
Return on Equity-732.74%
Return on Assets-96.77%

Miscellaneous

Employees47
Outstanding Shares16,440,000

AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions

What is AEterna Zentaris' stock symbol?

AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

How were AEterna Zentaris' earnings last quarter?

AEterna Zentaris Inc. (NASDAQ:AEZS) posted its quarterly earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.82) by $0.11. The biopharmaceutical company earned $0.24 million during the quarter, compared to analysts' expectations of $0.50 million. AEterna Zentaris had a negative net margin of 2,338.61% and a negative return on equity of 732.74%. View AEterna Zentaris' Earnings History.

When will AEterna Zentaris make its next earnings announcement?

AEterna Zentaris is scheduled to release their next quarterly earnings announcement on Wednesday, March, 21st 2018. View Earnings Estimates for AEterna Zentaris.

Where is AEterna Zentaris' stock going? Where will AEterna Zentaris' stock price be in 2018?

2 brokers have issued 1-year target prices for AEterna Zentaris' stock. Their forecasts range from $3.00 to $4.00. On average, they expect AEterna Zentaris' stock price to reach $3.50 in the next year. View Analyst Ratings for AEterna Zentaris.

What are Wall Street analysts saying about AEterna Zentaris stock?

Here are some recent quotes from research analysts about AEterna Zentaris stock:

  • 1. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (1/29/2018)
  • 2. Maxim Group analysts commented, "Summary Aeterna Zentaris announced its plan to file a new drug application (NDA) for Macrilen (macimorelin) for adults growth hormone deficiency (AGHD) in 3Q17, following its meeting with the FDA on March 29, 2017." (3/30/2017)

Are investors shorting AEterna Zentaris?

AEterna Zentaris saw a drop in short interest in January. As of January 12th, there was short interest totalling 797,677 shares, a drop of 30.9% from the December 29th total of 1,153,950 shares. Based on an average daily volume of 234,802 shares, the short-interest ratio is currently 3.4 days. Approximately 8.1% of the shares of the stock are sold short.

Who are some of AEterna Zentaris' key competitors?

Who are AEterna Zentaris' key executives?

AEterna Zentaris' management team includes the folowing people:

  • Carolyn Egbert, Independent Chairman of the Board
  • Michael Ward, President, Chief Executive Officer, Director
  • Jeffrey A. Whitnell CPA, Interim Chief Financial Officer (Age 58)
  • Richard Sachse M.D. Ph.D., Senior Vice President, Chief Scientific Officer, Chief Medical Officer
  • Jude Dinges, Chief Commercial Officer, Senior Vice President
  • Eckhard G. Gunther Ph.D., Vice President - Alliance Management
  • Michael Teifel, Vice President - Non-Clinical Sciences
  • John W. Sharkey Ph.D., Business Development Consultant (Age 60)
  • Philip Allen Theodore, Corporate Secretary (Age 64)
  • David A. Dodd, Director (Age 65)

How do I buy AEterna Zentaris stock?

Shares of AEterna Zentaris can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AEterna Zentaris' stock price today?

One share of AEterna Zentaris stock can currently be purchased for approximately $1.88.

How big of a company is AEterna Zentaris?

AEterna Zentaris has a market capitalization of $30.29 million and generates $910,000.00 in revenue each year. The biopharmaceutical company earns $-24,950,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis. AEterna Zentaris employs 47 workers across the globe.

How can I contact AEterna Zentaris?

AEterna Zentaris' mailing address is 315 Sigma Dr Ste 302D, SUMMERVILLE, SC 29486-7790, United States. The biopharmaceutical company can be reached via phone at +1-843-9003223 or via email at [email protected]


MarketBeat Community Rating for AEterna Zentaris (AEZS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  152 (Vote Underperform)
Total Votes:  397
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AEterna Zentaris (NASDAQ:AEZS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.50$3.50$4.33$4.33
Price Target Upside: 38.88% upside38.88% upside150.48% upside150.48% upside

AEterna Zentaris (NASDAQ:AEZS) Consensus Price Target History

Price Target History for AEterna Zentaris (NASDAQ:AEZS)

AEterna Zentaris (NASDAQ:AEZS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2018Maxim GroupSet Price TargetBuy$4.00HighView Rating Details
11/29/2017HC WainwrightSet Price TargetBuy$3.00MediumView Rating Details
1/8/2017Canaccord GenuitySet Price TargetBuy$7.50 -> $6.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

AEterna Zentaris (NASDAQ:AEZS) Earnings History and Estimates Chart

Earnings by Quarter for AEterna Zentaris (NASDAQ:AEZS)

AEterna Zentaris (NASDAQ AEZS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2018        
11/8/2017Q3 2017($0.41)($0.44)$0.24 millionViewN/AView Earnings Details
8/10/20176/30/2017($0.41)($0.46)$0.22 million$0.24 millionViewN/AView Earnings Details
5/8/20173/31/2017($0.33)($0.31)$0.85 million$0.26 millionViewListenView Earnings Details
3/15/201712/31/2016($0.73)($0.71)$0.40 million$0.30 millionViewN/AView Earnings Details
11/8/2016Q316($0.74)($0.61)$0.22 million$0.27 millionViewListenView Earnings Details
8/9/2016Q2 2016($1.19)($0.71)$0.10 millionViewN/AView Earnings Details
5/9/2016Q216($0.82)($0.71)$0.50 million$0.24 millionViewN/AView Earnings Details
3/29/2016Q415($1.30)($1.46)$0.25 million$0.10 millionViewN/AView Earnings Details
11/5/2015Q315($0.06)($0.07)$0.20 million$0.17 millionViewN/AView Earnings Details
8/13/2015Q215($0.08)($0.14)$0.55 million$0.20 millionViewListenView Earnings Details
5/7/2015Q1 2015($0.10)($0.13)$0.07 millionViewN/AView Earnings Details
3/17/2015Q414($0.16)$0.06$0.01 millionViewN/AView Earnings Details
11/4/2014Q3 2014($20.00)ViewN/AView Earnings Details
8/7/2014Q2 2014($9.00)ViewN/AView Earnings Details
5/8/2014Q1 2014($8.00)ViewN/AView Earnings Details
3/20/2014Q413($0.04)($0.22)$12.41 millionViewN/AView Earnings Details
11/5/2013Q3 2013($26.00)$13.00$2.22 million$21.06 millionViewN/AView Earnings Details
8/8/2013Q2 2013($28.00)$37.00$8.35 million$30.09 millionViewN/AView Earnings Details
5/7/2013Q1 2013($29.00)$7.00$16.60 millionViewN/AView Earnings Details
3/21/2013Q412($0.31)($0.29)$7.96 million$9.16 millionViewN/AView Earnings Details
11/13/2012Q312($0.43)($0.35)$8.38 million$7.10 millionViewN/AView Earnings Details
8/14/2012Q2 2012($41.99)($34.19)ViewN/AView Earnings Details
5/9/2012Q1 2012($53.99)($64.79)ViewN/AView Earnings Details
3/27/2012Q4 2011($53.99)($41.99)ViewN/AView Earnings Details
11/10/2011Q3 2011($53.99)$6.60ViewN/AView Earnings Details
8/10/2011Q2 2011($47.99)($70.19)ViewN/AView Earnings Details
5/18/2011Q1 2011($53.99)($58.19)ViewN/AView Earnings Details
3/22/2011Q4 2010($41.99)($18.00)ViewN/AView Earnings Details
11/9/2010Q3 2010($59.99)($73.19)ViewN/AView Earnings Details
8/12/2010Q2 2010($59.99)($36.59)ViewN/AView Earnings Details
5/13/2010Q1 2010($71.99)($55.79)ViewN/AView Earnings Details
3/24/2010Q4 2009($107.98)$116.38ViewN/AView Earnings Details
11/11/2009Q3 2009($119.98)($115.78)ViewN/AView Earnings Details
8/11/2009Q2 2009($137.97)($146.37)ViewN/AView Earnings Details
5/6/2009Q1 2009($89.98)($139.77)ViewN/AView Earnings Details
3/11/2009Q4 2008($161.97)($161.97)ViewN/AView Earnings Details
11/13/2008Q3 2008($161.97)($156.57)ViewN/AView Earnings Details
8/12/2008Q2 2008($161.97)($232.15)ViewN/AView Earnings Details
5/7/2008Q1 2008($137.97)($122.38)ViewN/AView Earnings Details
3/5/2008Q4 2007($113.98)($155.97)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

AEterna Zentaris (NASDAQ:AEZS) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.5 EPS
Next Year EPS Consensus Estimate: $-0.77 EPS

Dividends

Dividend History for AEterna Zentaris (NASDAQ:AEZS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AEterna Zentaris (NASDAQ AEZS)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

AEterna Zentaris (NASDAQ AEZS) News Headlines

Source:
DateHeadline
Head-To-Head Contrast: AEterna Zentaris (AEZS) & Esperion Therapeutics (ESPR)Head-To-Head Contrast: AEterna Zentaris (AEZS) & Esperion Therapeutics (ESPR)
www.americanbankingnews.com - February 20 at 9:12 PM
Biotech Forum Daily Digest For January 18thBiotech Forum Daily Digest For January 18th
seekingalpha.com - February 13 at 3:17 PM
AEterna Zentaris (AEZS) Downgraded by Zacks Investment ResearchAEterna Zentaris (AEZS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 29 at 5:00 PM
AEterna Zentaris Inc. (AEZS) Short Interest UpdateAEterna Zentaris Inc. (AEZS) Short Interest Update
www.americanbankingnews.com - January 29 at 1:20 AM
AEterna Zentaris (AEZS) Upgraded at Zacks Investment ResearchAEterna Zentaris (AEZS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - January 26 at 4:54 PM
AEterna Zentaris: Licensing Agreement Takes Out Dilution Risk - Seeking AlphaAEterna Zentaris: Licensing Agreement Takes Out Dilution Risk - Seeking Alpha
seekingalpha.com - January 24 at 3:18 PM
Biotech Stocks Research Reports Released on 22nd Century, Abeona Therapeutics, Acasti Pharma, and Aeterna ... - PR Newswire (press release)Biotech Stocks' Research Reports Released on 22nd Century, Abeona Therapeutics, Acasti Pharma, and Aeterna ... - PR Newswire (press release)
www.prnewswire.com - January 24 at 7:55 AM
5 Great Breakout Stocks Offering Superlative Returns5 Great Breakout Stocks Offering Superlative Returns
finance.yahoo.com - January 18 at 3:20 PM
Mid-Day Market Update: Dow Surges Over 150 Points; HTG ... - BenzingaMid-Day Market Update: Dow Surges Over 150 Points; HTG ... - Benzinga
www.benzinga.com - January 18 at 6:56 AM
Aeterna Zentaris Inc. Surges After Agreement With Strongbridge - Baystreet.caAeterna Zentaris Inc. Surges After Agreement With Strongbridge - Baystreet.ca
www.baystreet.ca - January 18 at 6:56 AM
44 Biggest Movers From Yesterday - Benzinga44 Biggest Movers From Yesterday - Benzinga
www.benzinga.com - January 18 at 6:56 AM
Aeterna Zentaris shares halted pending news - Seeking AlphaAeterna Zentaris shares halted pending news - Seeking Alpha
seekingalpha.com - January 18 at 6:56 AM
NVS Kymriah To Face FDA Again, AEZS Teams Up With SBBP, A Rival For EXAS? - NasdaqNVS' Kymriah To Face FDA Again, AEZS Teams Up With SBBP, A Rival For EXAS? - Nasdaq
www.nasdaq.com - January 18 at 6:56 AM
AEterna Zentaris (AEZS) PT Set at $4.00 by Maxim GroupAEterna Zentaris (AEZS) PT Set at $4.00 by Maxim Group
www.americanbankingnews.com - January 17 at 11:26 PM
Aeterna Zentaris shares halted pending newsAeterna Zentaris shares halted pending news
seekingalpha.com - January 17 at 7:25 AM
AEterna Zentaris (AEZS) Upgraded to Buy at Zacks Investment ResearchAEterna Zentaris (AEZS) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - January 16 at 4:36 PM
AEterna Zentaris (AEZS) Downgraded to "Hold" at Zacks Investment ResearchAEterna Zentaris (AEZS) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 4:28 PM
Aeterna Zentaris Inc. (AEZS)Aeterna Zentaris Inc. (AEZS)
finance.yahoo.com - January 11 at 3:19 PM
Stocks push slightly higher, President Trump prepares to sign tax bill into lawStocks push slightly higher, President Trump prepares to sign tax bill into law
finance.yahoo.com - December 23 at 8:33 PM
Aeterna Zentaris (AEZS) Offers Update on Litigation against David Dodd and Philip Theodore - StreetInsider.comAeterna Zentaris (AEZS) Offers Update on Litigation against David Dodd and Philip Theodore - StreetInsider.com
www.streetinsider.com - December 23 at 1:37 AM
Aeterna Zentaris Provides Update on Litigation against David Dodd and Philip TheodoreAeterna Zentaris Provides Update on Litigation against David Dodd and Philip Theodore
feeds.benzinga.com - December 22 at 5:48 PM
Aeterna Zentaris (AEZS) Reports FDA Approval of Macrilen for Diagnosis of AGHDAeterna Zentaris (AEZS) Reports FDA Approval of Macrilen for Diagnosis of AGHD
www.streetinsider.com - December 21 at 3:19 PM
(AEZS) (NQ) Higher; (PCG) (BBBY) - StreetInsider.com - StreetInsider.com(AEZS) (NQ) Higher; (PCG) (BBBY) - StreetInsider.com - StreetInsider.com
www.streetinsider.com - December 21 at 3:19 PM
Mid-Afternoon Market Update: Aeterna Zentaris Climbs Following FDA Approval Of Macrilen; Apogee Shares Slide - BenzingaMid-Afternoon Market Update: Aeterna Zentaris Climbs Following FDA Approval Of Macrilen; Apogee Shares Slide - Benzinga
www.benzinga.com - December 21 at 3:19 PM
IIROC Trade Resumption - Aeterna Zentaris Inc.IIROC Trade Resumption - Aeterna Zentaris Inc.
finance.yahoo.com - December 21 at 3:19 PM
Aeterna Zentaris stock soars toward 8-month high after Macrilen granted marketing approvalAeterna Zentaris' stock soars toward 8-month high after Macrilen granted marketing approval
finance.yahoo.com - December 21 at 3:19 PM
After-Hours Stock Movers 12/20: (AEZS) (VERI) (CORT) Higher; (PCG) (BBBY) Lower (more...) - StreetInsider.comAfter-Hours Stock Movers 12/20: (AEZS) (VERI) (CORT) Higher; (PCG) (BBBY) Lower (more...) - StreetInsider.com
www.streetinsider.com - December 21 at 6:25 AM
Aeterna Zentaris (AEZS) Reports FDA Approval of Macrilen for Diagnosis of AGHD - StreetInsider.comAeterna Zentaris (AEZS) Reports FDA Approval of Macrilen for Diagnosis of AGHD - StreetInsider.com
www.streetinsider.com - December 21 at 6:25 AM
Canadas Aeterna gets FDA approval for growth hormone deficiency testCanada's Aeterna gets FDA approval for growth hormone deficiency test
finance.yahoo.com - December 21 at 6:25 AM
Aeterna Zentaris Announces FDA Approval of Macrilen™ (macimorelin) for Diagnosis of Adult Growth Hormone DeficiencyAeterna Zentaris Announces FDA Approval of Macrilen™ (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency
finance.yahoo.com - December 21 at 6:25 AM
IIROC Trade Halt - Aeterna Zentaris Inc.IIROC Trade Halt - Aeterna Zentaris Inc.
finance.yahoo.com - December 21 at 6:25 AM
AEterna Zentaris Inc. (USA) (AEZS) Investors Celebrate FDA Approval; Shares SkyrocketAEterna Zentaris Inc. (USA) (AEZS) Investors Celebrate FDA Approval; Shares Skyrocket
finance.yahoo.com - December 21 at 6:25 AM
Aeterna Zentaris trading halted pending newsAeterna Zentaris trading halted pending news
seekingalpha.com - December 20 at 9:21 PM
FDA OKs Aeterna Zentaris Macrilen for diagnosis of adult growth hormone deficiency; shares up 53% after hoursFDA OKs Aeterna Zentaris' Macrilen for diagnosis of adult growth hormone deficiency; shares up 53% after hours
seekingalpha.com - December 20 at 9:21 PM
AEterna Zentaris Investment: A Risk Analysis - Seeking AlphaAEterna Zentaris Investment: A Risk Analysis - Seeking Alpha
seekingalpha.com - December 17 at 6:23 AM
Aeterna Zentaris: Where Is The Upside? A Valuation Of The Company - Seeking AlphaAeterna Zentaris: Where Is The Upside? A Valuation Of The Company - Seeking Alpha
seekingalpha.com - December 16 at 6:25 AM
AEZS: The Unique Selling Points Of Macrilen - Seeking AlphaAEZS: The Unique Selling Points Of Macrilen - Seeking Alpha
seekingalpha.com - December 15 at 6:18 AM
Aeterna Zentaris (AEZS) Interim Chief Financial Officer Departs - StreetInsider.comAeterna Zentaris (AEZS) Interim Chief Financial Officer Departs - StreetInsider.com
www.streetinsider.com - December 8 at 3:18 PM
Ahead of Big Catalyst, AEterna Zentaris Inc. (AEZS) Announced Departure of Interim Chief Financial OfficerAhead of Big Catalyst, AEterna Zentaris Inc. (AEZS) Announced Departure of Interim Chief Financial Officer
finance.yahoo.com - December 8 at 3:18 PM
Biotechs Flying Under The Radar - PR Newswire (press release)Biotech's Flying Under The Radar - PR Newswire (press release)
www.prnewswire.com - December 6 at 3:19 PM
HC Wainwright Analysts Give AEterna Zentaris (AEZS) a $3.00 Price TargetHC Wainwright Analysts Give AEterna Zentaris (AEZS) a $3.00 Price Target
www.americanbankingnews.com - November 29 at 7:30 PM
AEterna Zentaris (AEZS) Given a $4.00 Price Target by Maxim Group AnalystsAEterna Zentaris (AEZS) Given a $4.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - November 28 at 3:36 PM
Aeterna Zentaris (AEZS) Says MAA for Macrilen for Evaluation of Adult Growth Hormone Deficiency Accepted by EMAAeterna Zentaris (AEZS) Says MAA for Macrilen for Evaluation of Adult Growth Hormone Deficiency Accepted by EMA
www.streetinsider.com - November 28 at 3:18 PM
(AEZS) (TECD) Higher; (ASC) (CPRX) - StreetInsider.com - StreetInsider.com(AEZS) (TECD) Higher; (ASC) (CPRX) - StreetInsider.com - StreetInsider.com
www.streetinsider.com - November 28 at 7:37 AM
Aeterna Zentaris (AEZS) Says MAA for Macrilen for Evaluation of ... - StreetInsider.comAeterna Zentaris (AEZS) Says MAA for Macrilen for Evaluation of ... - StreetInsider.com
www.streetinsider.com - November 28 at 7:37 AM
BIIB & ALKS Team Up For MS Drug, REGNs Eylea Combo Fails Again, AEZS Rises - NasdaqBIIB & ALKS Team Up For MS Drug, REGN's Eylea Combo Fails Again, AEZS Rises - Nasdaq
www.nasdaq.com - November 28 at 7:37 AM
AEterna Zentaris Inc.’s (USA) (AEZS) Growth Hormone Drug Accepted for EU ReviewAEterna Zentaris Inc.’s (USA) (AEZS) Growth Hormone Drug Accepted for EU Review
finance.yahoo.com - November 28 at 7:37 AM
Aeterna Zentaris’ Marketing Authorization Application for Macrilen™ (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines AgencyAeterna Zentaris’ Marketing Authorization Application for Macrilen™ (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines Agency
finance.yahoo.com - November 28 at 7:37 AM
AEterna Zentaris Inc. (AEZS) Expected to Post Earnings of -$0.42 Per ShareAEterna Zentaris Inc. (AEZS) Expected to Post Earnings of -$0.42 Per Share
www.americanbankingnews.com - November 15 at 9:47 AM
 Brokerages Set $3.50 Target Price for AEterna Zentaris Inc. (AEZS) Brokerages Set $3.50 Target Price for AEterna Zentaris Inc. (AEZS)
www.americanbankingnews.com - November 14 at 1:50 AM

SEC Filings

AEterna Zentaris (NASDAQ:AEZS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AEterna Zentaris (NASDAQ:AEZS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AEterna Zentaris (NASDAQ AEZS) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.